Literature DB >> 9264375

Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia.

W Fielder1, U Graeven, S Ergün, S Verago, N Kilic, M Stockschläder, D K Hossfeld.   

Abstract

FLT4 represents a recently cloned member of class III receptor tyrosine kinases which include receptors for the angiogenic growth factor VEGF, namely FLT1 and KDR. The ligand of FLT4 has been identified as VEGF-C which shares sequence homology with VEGF and P1GF. In the adult FLT4 shows a restricted expression pattern that is limited to lymphatic endothelia and endothelia of some high endothelial venules (HEV). FLT4 has also been detected in some tumor cell lines including the hematopoietic line HEL. We therefore investigated expression of FLT4 and its ligand VEGF-C in fresh samples from patients with AML. Using a sensitive PCR method we detected FLT4 m-RNA in 15 of 41 patients with de novo AML at diagnosis or relapse and in three of 12 patients with secondary AML. FLT4 expression was confirmed by immunocytochemistry in a subgroup of the studied patient population. FLT4 was also found in leukemic cell line U937, but not TF-1 and KG1a. VEGF-C expression was found in leukemic samples of four of seven FLT4-positive and four of six FLT4-negative patients. U937 cells also produced VEGF-C m-RNA. Interestingly, FLT4 expression was not detected in bone marrow samples of 15 normal volunteer donors or in CD34-positive cells from three additional donors. Possible autocrine and paracrine growth stimulation of leukemic blasts by VEGF-C is currently being investigated in our laboratory.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264375     DOI: 10.1038/sj.leu.2400722

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  18 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  Vascular endothelial growth factor-C and its receptor type-3 expressed in acute lymphocytic leukemia cases with t(1;19).

Authors:  Ryosuke Shirasaki; Haruko Tashiro; Yoko Oka; Toshihiko Sugao; Tadashi Yamamoto; Mayumi Yoshimi; Nobu Akiyama; Kazuo Kawasugi; Naoki Shirafuji
Journal:  Int J Hematol       Date:  2011-07-06       Impact factor: 2.490

3.  Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.

Authors:  Elizabeth Larocque; N Naganna; Xiaochu Ma; Clement Opoku-Temeng; Brandon Carter-Cooper; Gaurav Chopra; Rena G Lapidus; Herman O Sintim
Journal:  Future Med Chem       Date:  2017-05-11       Impact factor: 3.808

4.  Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.

Authors:  S Dias; K Hattori; Z Zhu; B Heissig; M Choy; W Lane; Y Wu; A Chadburn; E Hyjek; M Gill; D J Hicklin; L Witte; M A Moore; S Rafii
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

5.  Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.

Authors:  M Skobe; L M Hamberg; T Hawighorst; M Schirner; G L Wolf; K Alitalo; M Detmar
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

Review 6.  The non-canonical role of vascular endothelial growth factor-C axis in cancer progression.

Authors:  Chu-An Wang; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-16

7.  The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis.

Authors:  Geraldine Siegfried; Ajoy Basak; James A Cromlish; Suzanne Benjannet; Jadwiga Marcinkiewicz; Michel Chrétien; Nabil G Seidah; Abdel-Majid Khatib
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 8.  Vascular endothelial growth factor signaling in acute myeloid leukemia.

Authors:  Kim R Kampen; Arja Ter Elst; Eveline S J M de Bont
Journal:  Cell Mol Life Sci       Date:  2012-07-26       Impact factor: 9.261

Review 9.  The role of VEGF in normal and neoplastic hematopoiesis.

Authors:  Hans-Peter Gerber; Napoleone Ferrara
Journal:  J Mol Med (Berl)       Date:  2002-12-14       Impact factor: 4.599

10.  A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia.

Authors:  Ji Yoon Lee; Sohye Park; Donghyun Curt Kim; Jae-Ho Yoon; Seung Hwan Shin; Woo-Sung Min; Hee-Je Kim
Journal:  J Clin Immunol       Date:  2013-02-13       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.